Cross-sectional surveillance study on carriage of pneumococcal and meningococcal bacteria and other nasopharyngeal pathogens in 24-month-old children and the parents performed in the thirteenth year after introduction of pneumococcal conjugate vaccination in The Netherlands National Immunization Programme

Cross-sectional surveillance study on carriage of pneumococcal and meningococcal bacteria and other nasopharyngeal pathogens in 24-month-old children and the parents performed in the thirteenth year after introduction of pneumococcal conjugate vaccination in The Netherlands National Immunization Programme - nasopharyngeal pneumococcal and meningococcal colonization (OKIDOKI-5)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46096

Enrollment

760

Registered

2018-08-20

Start date

2018-10-08

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

virale infectieziekten asymptomatic pneumococcal and meningococcal nasopharyngeal colonisation pneumococcal and meningococcal carriage

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: *The children have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with small increases in temperature or cold are seen as children with normal health, fever >38.5°C in the last two days is not considered as normal health) *The parents/legal guardians have to be willing and able to participate in the trial according to procedure *The child is 24-months-old (± 8 weeks) or for older siblings; the child is between 24 month (-4 weeks) and

Exclusion criteria

Exclusion criteria: For the children *Previous vaccinations with PCV using a vaccine and schedule that differs from the Dutch NIP of that age group *Previous vaccinations with MenACWY vaccine *Medical conditions that will severely affect immunological responses to vaccinations or nasopharyngeal carriage rates (certain chromosomal abnormalities or craniofacial abnormalities (like Trisomy 21, schisis), known or suspected immunodeficiency disease or other medical conditions);A parent/legal guardian who meets any of the following criteria will be excluded from participation in this study: *Medical conditions that will severely affect immunological responses to vaccinations or nasopharyngeal carriage rates (certain chromosomal abnormalities or craniofacial abnormalities (like Trisomy 21 or schisis), known or suspected immunodeficiency disease or other medical conditions)

Design outcomes

Primary

Measure	Time frame
Total pneumococcal vaccine and non-vaccine serotypes	—

Secondary

Measure	Time frame
pneumococcal and meningococcal presence by culture, pneumococcal and meningococcal density and multi-serotype carriage analysis using molecular methods, presence of other respiratory non-pneumococcal bacteria and viruses, antibiotic resistance of isolates, microbiome and salivary antibodies.	—

Countries

Netherlands

Outcome results